Evidence map›Paper›PMID 41425689›Full record

ArticleTherapeutic advances in endocrinology and metabolism2025

Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes.

Yung-Sheng Cheng, Chi-Hsiang Chung, Shih-Ming Kuo, Chih-Ping Lin, Tsu-Hsuan Weng, Sheng-Chiang Su, Chieh-Hua Lu, Feng-Chih Kuo, Wu-Chien Chien, Yao-Jen Liang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yung-Sheng ChengDivision of Pediatric Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.ORCID https://orcid.org/0000-0002-9516-8943
Chi-Hsiang ChungSchool of Public Health, National Defense Medical University, Taipei, Taiwan, ROC.
Shih-Ming KuoDivision of Pediatric Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.ORCID https://orcid.org/0009-0005-0632-7463
Chih-Ping LinDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Tsu-Hsuan WengDepartment of Medical Research, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Sheng-Chiang SuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Chieh-Hua LuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Feng-Chih KuoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Wu-Chien ChienSchool of Public Health, National Defense Medical University, Taipei, Taiwan, ROC.
Yao-Jen LiangGraduate Institute of Applied Science and Engineering Department and Institute of Life Science, Fu-Jen University, Number 510, Zhong-Zheng Road, Xin-Zhuang District, New Taipei City 242, Taiwan, ROC.ORCID https://orcid.org/0000-0001-5036-9592
Peng-Fei LiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, No. 325, Sec. 2, Chenggong Road, Neihu District, Taipei City 114, Taiwan, ROC.ORCID https://orcid.org/0000-0002-3044-7976

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may modulate asthma-related immune pathways, but evidence directly linking the use of GLP-1 RAs to asthma onset remains limited. Objectives: We aimed to evaluate whether the use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) is associated with a reduced risk and severity of asthma development. Design: This retrospective cohort study was designed to evaluate asthma onset and severity in patients with T2DM treated with GLP-1 RAs, using data from the National Health Insurance Database (2011-2015). Methods: Asthma onset and severity were evaluated in 1345 patients with T2DM treated with GLP-1 RAs from a cohort of 1,936,512 individuals, excluding those with pre-existing asthma. Asthma risk was assessed across four severity levels. Results: The study demonstrated a mean follow-up duration of 2.92 ± 1.82 years. Notably, treatment with GLP-1 RAs significantly reduced asthma risk compared with the non-GLP-1 RA group, as indicated by an adjusted hazard ratio (HR) of 0.67 (95% confidence interval (CI), 0.45-0.76), suggesting a consistent class effect. A protective trend was observed across various severity levels of asthma. The HRs for the GLP-1 RA group compared with the non-GLP-1 RA group for cases with no acute exacerbations (No-AE), acute exacerbations (AE), and status asthmaticus (Status) were 0.55 (95% CI, 0.37-0.62), 0.59 (95% CI, 0.39-0.66), and 0.83 (95% CI, 0.56-0.93), respectively. However, in cases requiring endotracheal intubation, the HR was 0.96 (95% CI, 0.65-1.09). Conclusion: Our study highlights a consistent effect of GLP-1 RAs in reducing asthma risk and severity, except in cases requiring endotracheal intubation, suggesting that GLP-1 RAs may contribute to reducing asthma incidence and severity in patients with T2DM.

Indexed as

acute exacerbationasthmaglucagon-like peptide-1 receptor agonistsreduce risktype 2 diabetes mellitus

Identifiers

PMID41425689
PMCPMC12712316

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.